文献速递胸部肿瘤

伴有致癌驱动分子改变的肺癌患者的靶向治疗

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
PubMed 文献 · J Clin Oncol · 2022-01-05

本综述总结了伴有驱动分子改变的肺癌靶向治疗现行标准。EGFR外显子19缺失和L858R突变、ALK和ROS1重排的靶向治疗已成熟,BRAF V600E、EGFR外显子20插入、KRAS G12C突变、MET外显子14改变及NTRK和RET重排的靶向药物不断获批。HER2外显子20插入突变等驱动基因的靶向治疗疗效数据正在涌现。文章还讨论了诊断分子检测的重要性、新型疗法的颅内疗效、最佳治疗序贯、靶向治疗在早期疾病中的作用及精准肿瘤学的未来方向。

要点

  • EGFR外显子19缺失和L858R突变、ALK和ROS1重排的靶向治疗已成熟。
  • BRAF V600E、EGFR外显子20插入、KRAS G12C、MET外显子14、NTRK和RET等靶向药物已获批。
  • HER2外显子20插入突变等驱动基因的靶向治疗疗效数据正在涌现。

核心结论

  • 非小细胞肺癌的新分类范式进一步以分子定义的亚群为特征,这些亚群可采用靶向治疗,治疗格局正变得日益复杂。

研究设计与样本

  • 本综述涵盖伴有驱动分子改变的肺癌靶向治疗的现行标准。

主要发现

  • EGFR外显子19缺失和L858R突变以及ALK和ROS1重排的靶向治疗已成熟。
  • 已获批的靶向治疗名单不断扩大,包括针对BRAF V600E、EGFR外显子20插入和KRAS G12C突变、MET外显子14改变以及NTRK和RET重排的靶向药物。
  • 此外还有许多其他致癌驱动基因,如HER2外显子20插入突变,其靶向治疗的疗效数据正在涌现。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lung cancer has traditionally been classified by histology. However, a greater understanding of disease biology and the identification of oncogenic driver alterations has dramatically altered the therapeutic landscape. Consequently, the new classification paradigm of non-small-cell lung cancer is further characterized by molecularly defined subsets actionable with targeted therapies and the treatment landscape is becoming increasingly complex. This review encompasses the current standards of care for targeted therapies in lung cancer with driver molecular alterations. Targeted therapies for EGFR exon 19 deletion and L858R mutations, and ALK and ROS1 rearrangements are well established. However, there is an expanding list of approved targeted therapies including for BRAF V600E, EGFR exon 20 insertion, and KRAS G12C mutations, MET exon 14 alterations, and NTRK and RET rearrangements. In addition, there are numerous other oncogenic drivers, such as HER2 exon 20 insertion mutations, for which there are emerging efficacy data for targeted therapies. The importance of diagnostic molecular testing, intracranial efficacy of novel therapies, the optimal sequencing of therapies, role for targeted therapies in early-stage disease, and future directions for precision oncology approaches to understand tumor evolution and therapeutic resistance are also discussed.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol. 2022. PMID: 34985916. doi:10.1200/JCO.21.01626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。